Scientists at Duke-NUS Medical School and the National University Health System (NUHS), together with an international team of researchers, have uncovered a complex interplay of factors that increase ...

Application supported by Phase 3 data reinforcing teclistamab regimens as a potential standard of care after at least one prior therapy1 ...

CEO Martin Lehr outlined the company’s strategy and upcoming clinical milestones at the 46th Annual TD Cowen Healthcare Conference, positioning the biotechnology company as a developer of T-cell ...

Radiation therapy treats roughly two-thirds of all cancer patients, yet healthy tissue has always absorbed collateral damage during treatment. A new generation of ultra-fast radiation delivery, ...

Lyell Immunopharma, Inc. ( LYEL) TD Cowen 46th Annual Health Care Conference March 2, 2026 9:10 AM EST ...

Awareness Month, which raises awareness, action, and amplifies the voices of individuals impacted by MM, a blood cancer in which abnormal plasma cells build up in the bone marrow, producing large ...

A breakthrough AI system is revolutionizing cancer immunotherapy by enabling scientists to design protein-based keys that train a patient s immune cells to attack cancer with extreme precision. This ...